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Abstract
Many lifestyle-related diseases are associated with low-grade inflammation and peroxisome proliferator activated receptor c
coactivator (PGC)-1a has been suggested to be protective against low-grade inflammation. However, whether these anti-
inflammatory properties affect acute inflammation is not known. The aim of the present study was therefore to investigate
the role of muscle PGC-1a in acute inflammation. Quadriceps muscles were removed from 10-week old whole body PGC-1a
knockout (KO), muscle specific PGC-1a KO (MKO) and muscle-specific PGC-1a overexpression mice (TG), 2 hours after an
intraperitoneal injection of either 0.8 mg LPS/g body weight or saline. Basal TNFa mRNA content was lower in skeletal
muscle of whole body PGC-1a KO mice and in accordance TG mice showed increased TNFa mRNA and protein level relative
to WT, indicating a possible PGC-1a mediated regulation of TNFa. Basal p65 phosphorylation was increased in TG mice
possibly explaining the elevated TNFa expression in these mice. Systemically, TG mice had reduced basal plasma TNFa
levels compared with WT suggesting a protective effect against systemic low-grade inflammation in these animals. While TG
mice reached similar TNFa levels as WT and showed more marked induction in plasma TNFa than WT after LPS injection,
MKO PGC-1a mice had a reduced plasma TNFa and skeletal muscle TNFa mRNA response to LPS. In conclusion, the present
findings suggest that PGC-1a enhances basal TNFa expression in skeletal muscle and indicate that PGC-1a does not exert
anti-inflammatory effects during acute inflammation. Lack of skeletal muscle PGC-1a seems however to impair the acute
TNFa response, which may reflect a phenotype more susceptible to infections as also observed in type 2 diabetes patients.
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Introduction
The transcriptional coactivator peroxisome proliferator activated
receptor c (PGC)-1a is known to influence many aspects of
metabolism and the role of PGC-1a as a master regulator of
mitochondrial biogenesis and oxidative metabolism in skeletal
muscle (SkM) has been confirmed repeatedly over the last decade
[1–3]. Recently it has been suggested that PGC-1a also exerts anti-
inflammatory effects. Hence overexpressing PGC-1a specifically in
SkM reduces an age-associated increase in serum TNFa as well as
TNFa mRNA and protein expression in SkM [4]. In accordance
TNFa mRNA expression and serum TNFa increases dramatically
after a single exercise bout in muscle specific PGC-1a knockout
mice, but not in WT [5]. Additionally, a negative correlation has
been reported between PGC-1a and TNFa mRNA levels in SkM of
type 2 diabetes patients independent of BMI [6]. Taken together,
these observations indicate that PGC-1a either directly or through
PGC-1a mediated adaptations in SkM provides anti-inflammatory
effects that potentially contribute to preventing low-grade inflam-
mation present in many life-style related diseases [7].
Inflammatory mediators have however also been suggested to
regulate PGC-1a expression [8–10]. Previous findings in human
cardiomyocytes indicate that nuclear factor kappa light chain-
enhancer of activated B cells (NFkB) binds to and inactivates PGC-
1a and that TNFa enhances such NFkB mediated PGC-1a
inhibition and the concomitant metabolic effects of PGC-1a [8]. In
addition, a recent study shows that lipopolysaccharide (LPS)
downregulates PGC-1a expression and reduces fat oxidation in
mouse cardiomyocytes and mouse heart in vivo [10]. On the other
hand, incubating C2C12 cells with TNFa has been reported to
increase PGC-1a dependent transcriptional activity, and LPS
treatment in mice has been shown to increase mitochondrial
respiration when PGC-1a is elevated in SkM [9]. This suggests that
PGC-1a itself is regulated during acute inflammation and these
somewhat contradicting observations underline, that the role of
PGC-1a in acute inflammation is not fully elucidated. Based on the
findings that PGC-1a mediated adaptations in SkM protect against
low-grade inflammation, it may be expected that SkM PGC-1a
impairs the ability to elicit a robust acute inflammatory response.
An acute inflammatory response is a conserved mechanism
highly essential for protection against invading microorganisms in
all species. The response involves the induction of both pro-
(TNFa, IL-6) and anti-inflammatory (IL-6 and IL-10) cytokines
mediated through p38 mitogen-activated protein kinases (p38) as
well as NFkB and c-Jun N-terminal kinase (JNK) signaling [11].
LPS treatment is a well-established and frequently used model to
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induce acute inflammation in humans and rodents [12–14].
Although circulating and infiltrating immune cells are seen as the
traditional responders during acute inflammation, LPS stimulation
has been shown to evoke p38, NFkB and JNK signaling and
concomitant production of cytokines like TNFa in many tissues
including SkM [9,14,15], which likely contributes to systemic
levels during acute inflammation. This is supported by the findings
that SkM functions as an endocrine organ [16] and that C2C12
cells incubated with LPS have been reported to produce and
secrete IL-6 to the medium [15].
The aim of the present study was to investigate whether the level
of PGC-1a expression in skeletal muscle affects an acute
inflammatory response locally in skeletal muscle and systemically.
This was addressed by giving LPS injections to PGC-1a whole
body knockout mice (KO), muscle specific PGC-1a knockout mice
(MKO) and transgenic mice overexpressing PGC-1a specifically in
SkM (TG). In addition, to investigate the potential secretion of
TNFa from muscle cells, primary myotubes from mouse skeletal
muscle were treated with LPS.
Materials and Methods
Ethics Statement
Experiments were approved by the ‘‘Animal Experiment
Inspectorate’’ in Denmark (permission number: 2009/561-1607)
and complied with the European convention for the protection of
vertebrate animals used for experiments and other scientific
purposes (Council of Europe, no. 123, Strasbourg, France, 1985).
Mice
Generation and phenotypes of the whole body PGC-1a KO
mice, MKO PGC-1a and TG PGC-1a mice used in the present
study have been described elsewhere [1,17,18]. Whole body PGC-
1a KO mice and littermate WT were obtained by crossbreeding of
heterozygous PGC-1a KO parents. MKO and littermate WT
were obtained by crossing a +/2 Cre, Flox/Flox parent with a
Flox/Flox parent, while TG and their littermate WT were
obtained by crossbreeding of TG and WT parents. The genotypes
of the mice were determined by PCR-based genotyping, as
previously described [19]. Mice were kept on a 12:12 hour light/
dark cycle and had access to water and standard rodent chow ad
libitum (Altromin no. 1324, Broga˚rden, Lynge, Denmark).
Experimental protocol
Each group consisted of 10 mice with equal number of male and
female mice. Ten weeks old PGC-1a KO, MKO PGC-1a, TG
PGC-1a and their respective littermate WT mice were given an
intraperitoneal injection of either saline as control or 0.8 mg LPS
(Sigma, St Louis, MO, USA) per gram mouse, dissolved in sterile
isotonic saline. Based on a preceding pilot study (data not shown)
and previous studies [14,15,20] showing a pronounced inflamma-
tory plasma and mRNA response 2 hours after LPS treatment, all
mice in the present study were euthanized by cervical dislocation
2 hours post injection. Trunk blood was collected after decapita-
tion and quadriceps muscles were quickly removed from all three
mouse strains and frozen in liquid nitrogen. In addition visceral
adipose tissue and liver were also removed from whole body PGC-
1a KO mice. Samples were stored at 280uC until analyzed.
Primary cell cultures
C57BL/6 mice were euthanized by cervical dislocation and
limb skeletal muscles were quickly dissected out and placed in
15 ml ice cold Dulbecco’s phosphate buffered saline solution
(DPBS; Invitrogen, Carlsbad, CA, USA) containing 1% glucose
and 0.5% penicillin/streptomycin (Invitrogen) and placed on ice.
Satellite cells were isolated and handled as previously described
[21]. One day prior to the experiment, the Fusion Medium (FM)
containing DMEM (Invitrogen) with 10% horse serum and 0.1%
L-glutamine was exchanged with DMEM without phenol red
(Invitrogen) containing 0.5% glucose, 0.05% L-glutamin and 0.1%
BSA (DMEM without phenol red). Cells were used for
experiments on day 8, where sufficient maturation and differen-
tiation of the myotubes were observed. On the day of the
experiment, the cells were washed in DMEM without phenol red.
Half of the cell cultures (n = 6, in 3 independent experiments) were
treated with 1.0 mg LPS/ml media and the other half was treated
with DMEM without phenol red as control. LPS was dissolved in
dimethyl sulfoxide (DMSO) and then diluted in DMEM without
phenol red. After 2 hours of incubation, the medium was collected
and the cells were harvested in Trizol reagent (Invitrogen). The
samples were stored at 280uC until analyzed.
Cell culture media
The TNFa protein content in media from the incubated
primary cell cultures was determined by Enzyme-linked immuno-
sorbent assay (ELISA) according to the protocol of the
manufacturer (eBioscience, San Diego, CA, USA). The absorption
at 450 nm was determined and the TNFa protein content in the
medium was calculated based on a standard curve generated from
a serial diluted standard.
Plasma cytokines
Plasma was processed from the blood samples by centrifugation
(2600 g for 15 min at 4uC). A MSD multiplex ELISA kit
(MesoScaleDiscovery, Gaithersburg, Maryland, USA) pre-coated
with antibodies against TNFa, IL-6 and IL-10 was used according
to the manufacturer’s protocol. MSD plates were measured on a
MSD Sector Imager 2400 plate reader. Raw data were measured
as electrochemiluminescence signal (light) detected by photode-
tectors and analyzed using the Discovery Workbench 3.0 software
(MSD). A standard curve was generated for each analyte and used
to determine the concentration of analytes in each sample.
RNA isolation and Reverse Transcription
Total RNA was isolated from ,20–25 mg crushed muscle
tissue, liver and adipose tissue with the guanidinium thiocyanate-
phenol-chloroform method as previously described [22,23] and in
the cell culture experiment with the Trizol method following the
manufacture’s guidelines (Invitrogen). The final pellets were re-
suspended in DEPC treated H2O containing 0.1 mM EDTA.
RNA was quantified by measuring the absorbance at 260 nm.
Reverse transcription (RT) was performed using the Superscript
II RNase H2 system (Invitrogen) as previously described [23] and
the cDNA samples were diluted in nuclease-free H2O.
Real-time PCR
Real-time PCR was performed using an ABI 7900 sequence-
detection system (Applied Biosystems, Foster City, CA). Primers
and TaqMan probes for amplifying gene-specific mRNA frag-
ments were designed using the database from ensemble.org and
Primer Express (Applied Biosystems). All TaqMan probes were 59-
FAM and 39-TAMRA labeled, and primers and Taqman probes
were obtained from TAG Copenhagen (Copenhagen, Denmark)
except GAPDH (59-FAM and 39-TAMRA) and beta-actin (59-VIC
and 39-nonflourescence), both obtained as a pre-developed assay
reagent (Applied Biosystems). The sequences are given in Table 1.
Real-time PCR was performed in triplicates in a total reaction
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volume of 10 ml using Universal Mastermix (Applied Biosystems)
except TNFa converting enzyme (TACE), which was amplified
using SYBGreen (Applied Biosystems). Cycle threshold (Ct) was
converted to a relative amount by use of a standard curve
constructed from a serial dilution of a pooled RT sample run
together with the samples. For muscle samples, target gene mRNA
content was for each sample normalized to single-stranded cDNA
content determined by OliGreen reagent (Molecular Probes,
Leiden, The Netherlands) as previously described [24]. For liver
and cell culture samples, target gene mRNA content was
normalized to beta-actin mRNA, which was unaffected by
genotype and treatment in the respective samples and for adipose
tissue samples, target gene mRNA content was normalized to
GAPDH mRNA, which was unaffected by genotype and
treatment in these samples.
Muscle lysate
Crushed ,20–25 mg quadriceps muscles were homogenized in
an ice-cold buffer (10% Glycerol, 20 mM Na-pyrophosphate,
150 mM NaCl, 50 mM Hepes, 1% NP-40, 20 mM b-glycerophos-
phate, 10 mM NaF, 1 mM EDTA, 1 mM EGTA, 2 mM PMSF,
10 mg/ml Aprotinin, 10 mg/ml Leupeptin, 2 mM Na3VO4, 3 mM
Benzamidine, pH 7.5) for 1 min using a tissuelyser (TissueLyser II;
QIAGEN, Germany) with 30 oscillations per second. Homogenates
were rotated end over end for 30 min at 4uC. The procedure with
the tissuelyser and the end over end rotation was repeated. Lysates
were generated by centrifugation at 16,000 g for 20 min at 4uC and
collection of the protein supernatant (lysate). Protein content in
lysates was measured by the bicinchoninic acid method (Thermo
Scientific, Rockford, IL, USA).
SDS-PAGE and western blotting
TNFa protein as well as phosphorylation of p38Thr180, Tyr182
and p65Ser536, the active subunit of NFkB, was measured in
muscle lysates by SDS-PAGE (10% or 15% Tris-HCl gel, BioRad,
Denmark) and western blotting using PVDF membrane and semi-
dry transfer. Twentyfive mg protein lysate was loaded for TNFa
and 15 mg protein lysate for p65 and p38 phosphorylation. After
the transfer, the PVDF membrane was blocked for 1 h at room
temperature (TBST+5% bovine serum albumin (BSA)) and then
incubated with primary antibody (1:1000 in TBST+5% BSA) over
night. Commercially available antibodies were used to detect
TNFa (Cell Signaling Technology #3707), p38Thr180, Tyr182 (Cell
Signaling Technology #4511) and p65Ser536 (Cell Signaling
Technology #3033). The following day, the membrane was
incubated with horseradish peroxidase-conjugated secondary
antibody (Dako, Denmark) for 1 h at room temperature (1:5000
in TBST+5% BSA). Immobilon Western (Millipore Corporation,
Table 1. Primer and Taqman probe sequences.
Forward primers Reverse primers Taqman Probes
TNFa 59 ATGGCCCAGACCCTCACA 39 59 TTGCTACGACGTGGGCTACA 39 59 TCAGATCATCTTCTCAAAATTCGAGTGACAAGC 39
IL-6 59 GCTTAATTACACATGTTCTCTGGGAAA 39 59 CAAGTGCATCATCGTTGTTCATAC 39 59 ATCAGAATTGCCATTGCACAACTCTTTTCTCAT 39
IL-10 59 AGAGAAGCATGGCCCAGAAAT 39 59 CAGGGGAGAAATCGATGACA 39 59 CAGGGGAGAAATCGATGACA 39
TACE 59 TGCAAGGCTGGGAAATGC 39 59 TTG CACGAGTTGTCAGTGTCAA 39
TLR4 59 TCTGATCATGGCACTGTTCTTCTC 39 59 CTGATCCATGCATTGGTAGGTAATATTA 39 59 CAGGAAGCTTGAATCCCTGCATAGAGGTAGTTC 39
F4/80 59 GGCTGCCTCCCTGACTTTC 39 59 TGCACTGCTTGGCATTGC 39 59 TCCTTTTGCAGTTGAAGTTTCCATATCCTTGG 39
Sequences for forward and reverse primers as well as Taqman probes used. Tumor necrosis factor (TNF)a, interleukin (IL)-6, IL-10, TNFa converting enzyme (TACE), toll-
like receptor 4 (TLR4), macrophage specific marker (F4/80).
doi:10.1371/journal.pone.0032222.t001
Figure 1. Plasma TNFa. Plasma tumor necrosis factor (TNF)a from whole body PGC-1a knockout (KO) (A), muscle specific PGC-1a KO (MKO) (B) and
muscle specific PGC-1a overexpression (TG) mice (C) and their respective littermate wild type (WT) mice, 2 hours after injection with either saline (Sal)
as control or lipopolysaccharide (LPS). Values are presented as means6 S.E. with n = 6–10 in each group, except WT of whole body KO strain injected
with saline where n = 3, due to lack of blood. *: Significantly different from Sal within given genotype, p,0.05. #: Significantly different from WT
within given treatment, p,0.05. Notice the bi-sected y-axis.
doi:10.1371/journal.pone.0032222.g001
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MA) was used as detection system and bands were visualized using
an Eastman Kodak Co. Image Station 2000 MM. Band intensity
was quantified using Kodak Molecular Imaging Software v. 4.0.3,
and protein content or phosphorylation was expressed as arbitrary
units relative to control samples loaded on each site of each gel.
Statistics
Two-way ANOVA was used to test the effect of LPS and
genotype within each mouse strain. Student Newman Keuls post
hoc test was used to locate differences. A T-test was used to test if
there was any difference in the basal levels between genotypes
within each mouse strain. All values are presented as means 6
S.E. A P,0.05 was considered significant.
Results
LPS-induced TNFa responses in primary myotubes
To verify that skeletal muscle produces and secretes TNFa in
response to LPS, primary myotubes isolated from C57BL/6 mice
were incubated with LPS. LPS treatment increased (p,0.05)
TNFa mRNA ,30 fold and TNFa protein in the media increased
(p,0.05) markedly from non-detectable levels in control cells to
,400 pg/ml (data not shown).
Plasma cytokines
Plasma TNFa. TG mice overexpressing PGC-1a specifically
in skeletal muscle had reduced basal plasma TNFa level
(0.660.5 pg/ml) compared with WT (2.661.2 pg/ml), whereas
there was no difference either in whole body PGC-1a KO or in
MKO PGC-1a mice compared with WT (fig. 1). In all groups,
LPS increased (p,0.05) the plasma TNFa level. Whereas there
was no genotype difference in the LPS-induced plasma TNFa
response between whole body PGC-1a KO mice and WT, MKO
PGC-1a mice had a reduced (p,0.05) response to LPS compared
with WT. Furthermore, as a consequence of the lowered plasma
TNFa level in TG PGC-1a mice in the basal state, a statistical
interaction was observed between TG PGC-1a mice and WT.
Thus the LPS-induced plasma TNFa response was higher (,2000
fold) in TG PGC-1a mice than in WT mice (,1000 fold).
Plasma IL-6. Basal plasma IL-6 levels were unaffected by
genotype. LPS induced a,100–400 fold increase (p,0.05) in plasma
IL-6 in all groups with no difference between genotypes (table 2).
Plasma IL-10. Basal plasma IL-10 levels were unaffected by
genotype. LPS induced a ,20–30 fold increase (p,0.05) in plasma
IL-10 in all groups with no difference between genotypes (table 2).
Basal and LPS-induced mRNA levels in skeletal muscle
TNFa mRNA. In the basal state, whole body PGC-1a KO
mice had ,60% lower (p,0.05) TNFa mRNA content in skeletal
muscle than WT and in line with this, TG mice had,2 fold higher
(p,0.05) TNFa mRNA content than WT, whereas no significant
difference was detected between MKO and WT despite a visual
,20% reduction in MKO. LPS injections increased (p,0.05) the
TNFa mRNA level ,13–60 fold in all groups. While no genotype
differences were observed in the LPS response in the whole body
KO and TG strains, the TNFa mRNA level after LPS treatment
was in MKO mice ,50% lower (p,0.05) than in WT (fig. 2).
TACE mRNA. To further examine the regulation of TNFa, a
metalloproteinase, TACE, which cleaves the membrane-
associated precursor of TNFa to the soluble and biological
active form of TNFa, was analyzed. In general, MKO mice had
30–40% lower (p,0.05) TACE mRNA levels in SkM than WT
mice, both at basal conditions and after LPS injections. No
difference was observed in whole body PGC-1a KO or TG mice
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relative to WT. LPS had no effect on TACE mRNA levels in any
of the strains (table 3).
TLR4 mRNA. There were no differences in either basal
TLR4 mRNA expression or after LPS injections in any of the
strains (table 3).
IL-6 mRNA. MKO mice had ,50% lower (p,0.05) basal
SkM IL-6 mRNA level than WT, whereas no genotype differences
were observed in the basal IL-6 mRNA level in the whole body
KO or TG mouse strain. In all groups, LPS induced a 130–400
fold increase (p,0.05) in IL-6 mRNA with no genotype
differences (table 3).
IL-10 mRNA. In the basal state, whole body PGC-1a KO
mice had ,55% lower (p,0.05) SkM IL-10 mRNA level than
WT, whereas there were no significant genotype differences in the
MKO (despite a visual 57% reduction) or TG strains. LPS
increased (p,0.05) the IL-10 mRNA content ,2–6 fold in all
groups with no significant difference between genotypes (table 3).
F4/80 mNRA. There were no genotype differences in the
mRNA level of the macrophage specific marker, F4/80, in SkM of
any of the strains and LPS had no effect on the F4/80 mRNA
level, indicating no LPS-induced recruitment of macrophages to
skeletal muscle 2 hours after LPS treatment (table 3).
TNFa protein in skeletal muscle
TNFa protein content. TG mice had ,9 fold higher
(p,0.05) basal SkM TNFa protein level relative to WT, while
there were no genotype differences in whole body KO and MKO
PGC-1a mouse strains at basal conditions. LPS did not alter SkM
TNFa protein content in any mouse strain, but MKO mice
treated with LPS had ,30% lower (p,0.05) TNFa protein than
WT treated with LPS (fig. 2).
Basal and LPS-induced intracellular signaling in skeletal
muscle
Phosphorylation of p65ser536. Basal p65 phosphorylation
was not affected by genotype in the whole body PGC-1a KO and
MKO strains, but notably TG mice overexpressing PGC-1a in
skeletal muscle had ,40% higher (p,0.05) basal SkM p65
phosphorylation than WT mice. This may explain the elevated
resting TNFa mRNA and protein level in these mice. LPS
increased (p,0.05) p65 phosphorylation ,30–70% in all three
mouse strains. The TG mice reached ,40% higher (p,0.05) p65
phosphorylation level after LPS treatment than WT, whereas
there were no differences between whole body PGC-1a KO or
MKO mice and their corresponding WT (fig. 3 and 4).
Figure 2. TNFa mRNA and protein content in quadriceps. Tumor necrosis factor (TNF)a mRNA and protein in quadriceps muscle from whole
body PGC-1a knockout (KO) (A,D), muscle specific PGC-1a KO (MKO) (B,E) and muscle specific PGC-1a overexpression (TG) mice (C,F) and their
respective littermate wild type (WT) mice, 2 hours after injection with either saline (Sal) as control or lipopolysaccharide (LPS). Values are presented as
means 6 S.E. with n = 10 in each group. *: Significantly different from Sal within given genotype, p,0.05. #: Significantly different from WT within
given treatment, p,0.05.
doi:10.1371/journal.pone.0032222.g002
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Phosphorylation of p38Thr180, Tyr182. LPS induced a similar
,2 fold increase (p,0.05) in p38 phosphorylation in TG and WT
mice, whereas no significant LPS-induced p38 phosphorylation
was observed in the whole body PGC-1a KO or the MKO PGC-
1a strain. No genotype differences were observed in the LPS-
induced p38 phosphorylation in SkM in any of the strains (table 3).
Basal and LPS-induced mRNA levels in liver and adipose
tissue from whole body PGC-1a KO mice
To examine whether PGC-1a regulates the response to acute
LPS-induced inflammation in other inflammatory tissues, liver and
adipose tissue mRNA was analyzed from whole body PGC-1a KO
mice and WT.
TNFa and IL-6 mRNA content. No genotype differences
were observed in TNFa and IL-6 mRNA in liver or adipose tissue
in the basal state. LPS induced a 6–89 fold increase (p,0.05) in
TNFa and IL-6 mRNA in liver and adipose tissue with no
difference between WT and KO mice (table 4).
TACE mRNA content. There was no genotype difference in
TACE mRNA level in the liver or the adipose tissueat basal
conditions and no changes with LPS were observed (table 4).
IL-10 mRNA content. In the basal state, no genotype
differences were observed in IL-10 mRNA in either the liver or
adipose tissue. LPS increased (p,0.05) the IL-10 mRNA level in
the liver similarly in KO and WT mice. In the adipose tissue, IL-
10 mRNA only increased significantly (p,0.05) in WT, whereas
only visual increase (p = 0.094) were observed in PGC-1a KO
mice in response to LPS treatment (table 4).
F4/80mRNA content. No genotype differences were observed
in F4/80 mRNA content in either the liver or adipose tissue in the
basal state. F4/80 mRNA was unaffected by LPS treatment in both
liver and adipose tissue from WT and KO mice (table 4).
Discussion
The main findings of the present study are that whole body
PGC-1a KO mice had a reduced basal TNFa mRNA level and
Figure 3. Phosphorylation of p65. Phosphorylation of p65ser536 in quadriceps muscle from whole body PGC-1a knockout (KO) (A), muscle specific
PGC-1a KO (MKO) (B) and muscle specific PGC-1a overexpression (TG) mice (C) and their respective littermate wild type (WT) mice, 2 hours after
injection with either saline (Sal) as control or lipopolysaccharide (LPS). Values are presented as mean s6 S.E. with n = 10 within each group.
*: Significantly different from Sal within given genotype, p,0.05. #: Significantly different from WT within given treatment, p,0.05.
doi:10.1371/journal.pone.0032222.g003
Table 3. Skeletal muscle mRNA and phosphorylation levels.
Whole body PGC-1a KO strain PGC-1a MKO strain TG PGC-1a strain
WT WT KO KO WT WT MKO MKO WT WT TG TG
Sal LPS Sal LPS Sal LPS Sal LPS Sal LPS Sal LPS
TACE mRNA 160.1 1.160.1 0.960.1 1.160.2 160.2 160.2 0.660.2# 0.760.1# 160.04 1.160.1 1.160.1 1.260.1
TLR4 mRNA 160.1 160.1 160.1 1.260.1 160.2 160.2 0.660.2 0.960.2 160.1 0.960.1 0.960.1 0.860.1
IL-6 mRNA 160.3 213645* 1.760.5 231647* 160.2 230653* 0.560.1# 183670* 160.2 130625* 0.660.2 129640*
IL-10 mRNA 160.1 4.860.4* 0.460.1# 2.560.4* 160.3 2.260.5* 0.460.1 2.060.4* 160.1 2.960.3* 160.2 2.560.5*
F4/80 mRNA 160.1 1.060.1 1.160.2 0.960.2 160.3 0.960.2 0.460.2 0.860.2 160.1 1.0160.1 1.160.1 0.760.1
p38-p (AU) 160.2 1.360.2 1.260.2 1.660.1 160.3 160.2 0.460.04 1.060.1 160.1 1.560.1* 0.760.1 1.660.2*
TNFa converting enzyme (TACE), toll-like receptor 4 (TLR4), interleukin (IL)-6, IL-10, macrophage specific marker (F4/80) mRNA as well as p38Thr180, Tyr182 phosphorylation
(p38-p) in quadriceps muscle from whole body PGC-1a knockout (KO), muscle specific PGC-1a KO (MKO) and muscle specific PGC-1a overexpression (TG) mice and their
respective littermate wild type (WT) mice, 2 hours after injection with either saline (Sal) as control or lipopolysaccharide (LPS). Values are presented as means6 S.E. with
n= 10 in each group.
*: Significantly different from Sal within given genotype, p,0.05.
#: Significantly different from WT within given treatment, p,0.05.
doi:10.1371/journal.pone.0032222.t003
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that mice overexpressing PGC-1a in skeletal muscle increased the
basal TNFa mRNA and protein content in skeletal muscle,
suggesting a PGC-1a mediated regulation of TNFa expression in
skeletal muscle. However, basal plasma TNFa was reduced in mice
overexpressing PGC-1a suggesting diminished secretion of TNFa
and indicating that high TNFa levels in SkM do not lead to systemic
low-grade inflammation. In addition, while high PGC-1a levels in
skeletal muscle elicited a more marked LPS-induced plasma TNFa
response, muscle specific knockout of PGC-1a resulted in a lower
LPS-induced plasma TNFa and TNFa mRNA response, poten-
tially reflecting a phenotype more susceptible to infections.
By use of three different PGC-1a mice models, the present study
provides new insight to the role of SkM PGC-1a in basal and acute
inflammation. The present findings that LPS treatment resulted in
similar TNFa, IL-6 and IL-10 levels in skeletal muscle and plasma
in TG and WT mice provide evidence that high levels of PGC-1a in
SkM do not alter the level of inflammatory markers during acute
inflammation. Of notice is however, that although the TG PGC-1a
mice had a lower basal plasma TNFa level, LPS elicited a more
marked fold increase in these mice. In accordance, the reduced
LPS-induced TNFa response in MKO PGC-1a mice both
systemically and in skeletal muscle indicates that lack of PGC-1a
or PGC-1a mediated metabolic adaptations impair the ability to
respond to acute inflammation. Together this suggests that high
SkM PGC-1a does not exert anti-inflammatory effects during acute
inflammation and SkM PGC-1a is required for a normal acute
inflammatory response. Interestingly the observed responses in
PGC-1a MKO and to some extent whole body PGC-1a KO mice,
resemble the previously reported attenuations in LPS-induced
plasma TNFa response in type 2 diabetes patients [25]. This may
suggest that low levels of PGC-1a in skeletal muscle, as observed in
physically inactive subjects [26] and in type 2 diabetes patients [27],
impair the inflammatory response to invading pathogens.
TLR4 is the main receptor mediating LPS-induced responses in
SkM. The observed similar levels of TLR4 mRNA independent of
genotype and treatment indicates, that the observed lower plasma
TNFa and SkM TNFa mRNA in MKO PGC-1a mice than WT
in the present study are not due to a difference at the receptor
level. The observed LPS-induced increase in phosphorylation of
the active subunit of NFkB, p65, and to some extent p38 signaling
supports that both NFkB and p38 contributed to the inflammatory
response after LPS treatment in the present study. However, lack
of genotype differences in the LPS-induced changes in signaling
indicates that neither NFkB (p65 phosphorylation) nor p38
signaling can explain the attenuated responses in plasma TNFa
and TNFa mRNA in SkM observed in MKO PGC-1a mice.
Differences in NFkB or p38 signaling, earlier than 2 hour after
LPS injections, of course can not be ruled out. The more marked
fold increase in plasma TNFa in TG mice upon LPS treatment
may on the other hand be linked to the higher p65 phosphory-
lation level in TG than WT. However, the unaffected TNFa
protein content in TG mice in response to LPS is as such in
accordance with such a mechanism as more secretion could keep
the increased level constant. But the similar TNFa mRNA
response in TG and WT does not support that a difference in
NFkB signaling alone is responsible for the more marked plasma
Table 4. mRNA expression in adipose tissue and liver from whole body PGC-1a KO mice.
Adipose tissue Liver
WT WT KO KO WT WT KO KO
Sal LPS Sal LPS Sal LPS Sal LPS
TNFa mRNA 160.4 12.262.1* 1.360.4 7.661.0* 160.2 36.263.5* 1.260.2 29.362.9*
TACE mRNA 160.2 2.260.6 1.360.2 1.060.2 160.2 1.260.1 0.960.1 1.060.1
IL-6 mRNA 160.3 38.867.2* 1.761.2 22.667.1* 160.3 88.869.7* 1.660.5 63.4610.5*
IL-10 mRNA 160.2 4.060.9* 1.260.2 1.860.3 160.4 6.761.3* 1.060.2 5.060.6*
F4/80 mRNA 160.2 1.560.4 1.160.2 0.460.1 160.1 0.960.1 1.060.2 0.860.1
Tumor necrosis factor (TNF)a, TNFa converting enzyme (TACE), interleukin (IL)-6, IL-10, macrophage specific marker (F4/80) mRNA in adipose tissue and liver from whole
body PGC-1a knockout (KO) and WT mice, 2 hours after injection with either saline (Sal) as control or lipopolysaccharide (LPS). Values are presented as means 6 S.E.
with n = 10 in each group.
*: Significantly different from Sal within given genotype, p,0.05.
doi:10.1371/journal.pone.0032222.t004
Figure 4. Representative blots. Representative blot of tumor necrosis factor (TNF)a protein, phosphorylation of p65 protein (p65-p) and
phosphorylation of p38 (p38-p) in quadriceps muscle from whole body PGC-1a knockout (KO), muscle specific PGC-1a KO (MKO) and muscle specific
PGC-1a overexpression (TG) mice and their respective littermate wild type (WT) mice, 2 hours after injection with either saline (Sal) as control or
lipopolysaccharide (LPS).
doi:10.1371/journal.pone.0032222.g004
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TNFa response in TG mice. As the LPS-induced SkM IL-6 and
IL-10 mRNA and plasma levels are independent of genotype, the
regulatory mediators and signaling factors involved in eliciting the
observed TNFa genotype difference in MKO PGC-1a mice in
response to LPS injections appear to be TNFa specific.
Interestingly, the finding that MKO PGC-1a mice, both in the
basal state and in response to LPS, had reduced SkM mRNA
expression of the TNFa regulatory enzyme TACE [28,29]
indicates that these mice may have a decreased ability to cleave
TNFa into its biological active form and thereby a reduced
secretion of TNFa protein from SkM relative to WT. Such a
mechanism may at least to some extent contribute to the observed
impaired LPS-induced plasma TNFa response when PGC-1a is
lacking in SkM.
The findings that whole body PGC-1a KO mice had lowered
basal TNFa mRNA level and that TG mice had elevated basal
TNFa mRNA and protein level in skeletal muscle compared with
WT are in contrast to previous observations in 22 months old TG
PGC-1a mice [4] and young MKO PGC-1a mice [6]. The
elevated TNFa levels in skeletal muscle of TG mice in the present
study may be explained by the observed higher level of basal p65
phosphorylation in skeletal muscle of TG mice. NFkB is activated
by several different stress associated stimuli such as LPS and TNFa
[30], but is also known to be a redox-sensitive transcription factor.
An increased basal p65 activity in TG mice could possibly be due
to an imbalance in ROS production and antioxidant defense,
which could lead to an altered redox state in the mitochondria of
these mice. However, based on enhanced superoxide dismutase 2
protein content in skeletal muscle of TG PGC-1a mice in a
previous [4] and the present study (data not shown) as well as
reduced protein carbonylation and oxidized nucleic acids in old
TG PGC-1a mice compared with age-matched controls [4], there
are no indications of elevated ROS in SkM muscle of TG PGC-1a
overexpression mice. Thus, increased mitochondrial ROS levels
do not seem to be the explanation for the elevated basal p65
phosphorylation and the mechanism responsible for the enhanced
p65 phosphorylation in SkM of TG mice remains to be
determined.
The finding that TG PGC-1a mice had elevated SkM TNFa
mRNA and protein and reduced plasma TNFa relative to WT in
the basal state, while there were no genotype differences in SkM
and plasma for IL-6 and IL-10, again indicates a TNFa specific
regulation. As TACE is required for the conversion of the TNFa
precursor to circulating TNFa, a specific regulation of TACE
could potentially have contributed to the observed PGC-1a
dependent difference. However, the observed similar TACE
mRNA levels in SkM of WT and TG mice indicate that the
amount of TACE is not responsible for the observed differences
between TNFa expression in SkM and systemic levels in TG mice
in the basal state, although the present study cannot elucidate
whether the activity of TACE is altered in these mice. Another
possible explanation for the discrepancy could be that the
contribution from skeletal muscle plays a minor role regarding
systemic plasma TNFa levels, because TNFa released from
skeletal muscle is diluted in the circulation. Cytokine production
is usually believed to originate from traditional immune cells like
macrophages, lymphocytes and monocytes in the blood stream
and infiltrated in various tissues. Adipose tissue and the liver are
also both known to respond to acute inflammation, which is also
supported by the present increases in TNFa, IL-6 and IL-10
mRNA in liver and adipose tissue in response to LPS. But as
skeletal muscle is the largest organ of the body and previously has
been shown to produce cytokines [14,31,32], it may be speculated
that skeletal muscle plays a significant overall role during acute
inflammation. The present observation that primary myotubes
incubated with LPS produced and secreted TNFa supports that
skeletal muscle may be an important endocrine tissue during acute
inflammation and suggests that skeletal muscle could be classified
as an immunological tissue. In addition, the findings that the
mRNA level of the macrophage specific marker F4/80 was
unchanged with LPS treatment, suggest that the inflammatory
response does not originate from newly recruited macrophages but
rather resident macrophages or myofibers as suggested from the
cell culture results. The magnitude by which SkM contributes to
the circulating cytokine level after LPS treatment is difficult to
assess and additional studies are needed to elucidate this aspect.
The present finding that overexpression of PGC-1a in skeletal
muscle decreased the systemic plasma TNFa level supports a
previous study showing that 22 months old TG PGC-1a mice
were protected against an age-associated increase in serum TNFa
[4]. Because elevated systemic TNFa has been associated with
obesity [33] and type 2 diabetes [34] and TNFa is known to
induce insulin resistance in vitro [35] and in vivo [36], the lowered
plasma TNFa in TG mice would therefore be expected to have
beneficial effects. Such a potential ability of high SkM PGC-1a to
protect against systemic low-grade inflammation and at the same
time posesses the ability to elicit a robust acute inflammatory
response underlines that different molecular mechanism mediate
these processes. Still, it may be noted, that no previous studies
have reported improvements in insulin sensitivity in young TG
PGC-1a mice and in fact when fed a high-fat diet for 3 weeks, TG
PGC-1a mice become insulin resistant compared with WT
controls [37]. In addition, the basal plasma TNFa level in the
present study was relatively low (,3 pg/ml) in both TG and WT
mice and therefore, the observed genotype difference in plasma
TNFa may not necessarily result in metabolic differences at this
age.
Finally, to elucidate the potential role of PGC-1a in the acute
inflammatory response in other tissues than skeletal muscle, the
liver and adipose tissue of whole body PGC-1a KO mice were
examined. The observed similar LPS-induced TNFa, IL-6 and IL-
10 mRNA responses in liver and adipose tissue from whole body
PGC-1a KO mice and WT mice does not indicate that PGC-1a is
necessary for a full inflammatory response in these tissues.
In conclusion, PGC-1a seems to be important for basal TNFa
expression in skeletal muscle, potentially via effects on p65
phosphorylation. While mice overexpressing PGC-1a in SkM
showed more marked plasma TNFa induction and reaching
similar TNFa levels after LPS injection as WT, lack of PGC-1a
and/or lack of PGC-1a mediated metabolic regulation in skeletal
muscle impair a LPS-induced TNFa response both systemically
and in skeletal muscle. This suggests that low levels of SkM PGC-
1a could lead to an inflexible phenotype with impaired ability to
cope with infections. Whether such PGC-1a associated effects are
related to direct effects of PGC-1a or are secondary effects of
PGC-1a mediated metabolic regulation remains to be determined.
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